Combination Treatment for HIV/HCV Coinfection Shown Effective in Phase 3 Trial

Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.

Results of a phase 3 study published September 6, 2014 in the journal Clinical Infectious Disease demonstrates the efficacy of Janssen's simeprevir (Olysio) in combination with peginterferon and ribavirin in patients with genotype-1 hepatitis C and HIV-1 coinfection.

To read the rest of the article on www.SpecialtyPharmacyTimes.com, click here.

Related Content:

HepatitisHIVRetail
Pharmacists Play Essential Role in Addressing Health Care Disparities
FDA to Revise Labeling for Prescription Cough Medicine Following Overdose Concerns in Young Children
Study: HIV Infection Leaves ‘Memory’ in Cells, Resulting in Persistent Comorbidities